Thyroid : official journal of the American Thyroid Association · 2026
Beyond the Eyes: Is Teprotumumab Effective for Thyroid Dermopathy?
СтатьяКлинический случайОбзорПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hamadi Dana, Saad-Omer Suhail, Toro-Tobon David, Stan Marius N
Аннотация
BACKGROUND: Pretibial dermopathy (PTD) is a rare, disfiguring manifestation of Graves' disease. The shared pathophysiology with thyroid eye disease (TED), centered on fibroblast activation via a thyroid-stimulating hormone receptor and insulin-like growth factor-1 receptor (IGF-1R) complex, provides a strong rationale for using the IGF-1R inhibitor, teprotumumab.
METHODS: We present a case series of five patients with severe PTD and concomitant TED who were treated with teprotumumab. A review of reported cases in the literature was also conducted.
RESULTS: All patients experienced significant clinical improvement, including regression of skin thickening as well as enhanced functional capacity. Side effects included mild hearing loss, muscle cramps, and fatigue. One patient experienced a severe gastrointestinal event requiring treatment discontinuation, while those experiencing a recurrence of PTD, responded to a second course of therapy.
CONCLUSIONS: Teprotumumab showed promising efficacy in the treatment of PTD. Further studies are needed to confirm its durability and safety.
METHODS: We present a case series of five patients with severe PTD and concomitant TED who were treated with teprotumumab. A review of reported cases in the literature was also conducted.
RESULTS: All patients experienced significant clinical improvement, including regression of skin thickening as well as enhanced functional capacity. Side effects included mild hearing loss, muscle cramps, and fatigue. One patient experienced a severe gastrointestinal event requiring treatment discontinuation, while those experiencing a recurrence of PTD, responded to a second course of therapy.
CONCLUSIONS: Teprotumumab showed promising efficacy in the treatment of PTD. Further studies are needed to confirm its durability and safety.